Barnett, C., Grinberg, Y., Ghani, M., Rogaeva, E., Katzberg, H., St George-Hyslop, P., & Bril, V. (2012). Fcγ receptor polymorphisms do not predict response to intravenous immunoglobulin in myasthenia gravis.

Blackhouse, G., Gaebel, K., Xie, F., Campbell, K., Assasi, N., Tarride, J. E., ... & Goeree, R. (2010). Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.

Boërio, D., Créange, A., Hogrel, J. Y., Guéguen, A., Bertrand, D., & Lefaucheur, J. P. (2010). Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.

Cojocaru, M., Cojocaru, I. M., Negreş, S., Popa, F., Purcărea, V. L., & Arsene, A. L. (2011). Intravenous immunoglobulin therapy in neurological diseases.FARMACIA, 59(6), 737-741.

Eftimov, F., Vermeulen, M., van Doorn, P. A., Brusse, E., van Schaik, I. N., van den Berg, L. H., ... & Hadden, R. D. M. (2012). Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology,78(14), 1079-1084.

Eienbröker, C., Seitz, F., Spengler, A., Kurz, H., Seipelt, M., Sommer, N., ... & Tackenberg, B. (2014). Intravenous immunoglobulin maintenance treatment in myasthenia gravis: A randomized, controlled trial sample size simulation.Muscle & nerve, 50(6), 999-1004.

Elovaara, I., Apostolski, S., van Doorn, P., Gilhus, N. E., Hietaharju, A., Honkaniemi, J., ... & Udd, B. (2012). Intravenous immunoglobulin in the treatment of neurological diseases. European Handbook of Neurological Management, Volume 2, Second Edition, 111-127.

Gaebel, K., Blackhouse, G., Campbell, K., Robertson, D., Xie, F., Assasi, N., ... & Goeree, R. (2010). Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Open Medicine, 4(3), e154.

Gajdos, P., Chevret, S., & Toyka, K. (2008). Intravenous immunoglobulin for myasthenia gravis (Review). The Cochrane Library.

Gamez, J. (2014). Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis. Clinical & Experimental Immunology, 178(S1), 134-135.

Gibson, G. (2012). The challenges of diagnosis and treatment of the chronic demyelinating neuropathies.

Gilardin, L., Bayry, J., & Kaveri, S. V. (2015). Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ: Canadian Medical Association journal/journal de l'Association medicale canadienne, 187(4), 257.

Hahn, A. F., Beydoun, S. R., Lawson, V., Oh, M., Empson, V. G., Leibl, H., ... & Koski, C. L. (2013). A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System, 18(4), 321-330.

Hedley, L. (2011). When a patient with myasthenia gravis can have intravenous immunoglobulin.The Pharmaceutical Journal, Volume 287(7660),17-23.

Heatwole, C., Johnson, N., Holloway, R., & Noyes, K. (2011). Plasma Exchange vs. Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study. Journal of clinical neuromuscular disease, 13(2), 85.

Hughes, R., Bensa, S., Willison, H., Van Den Bergh, P., Comi, G., Illa, I., ... & Swan, A. (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of neurology, 50(2), 195-201.

Eftimov, F., Winer, J. B., Vermeulen, M., de Haan, R., & van Schaik, I. N. (2009). Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. The Cochrane Library.

Keogh, M., Sedehizadeh, S., & Maddison, P. (2011). Treatment for Lambert‐Eaton myasthenic syndrome. The Cochrane Library.

Koski, C. L. (2014). Treatment of Multifocal Motor Neuropathy with Intravenous Immunoglobulin. Journal of clinical immunology, 34(1), 127-131.

Latov, N., Deng, C., Dalakas, M. C., Bril, V., Donofrio, P., Hanna, K., ... & van Doorn, P. A. (2010). Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.Archives of neurology, 67(7), 802-807.

Liew, W. K., Powell, C. A., Sloan, S. R., Shamberger, R. C., Weldon, C. B., Darras, B. T., & Kang, P. B. (2014). Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA neurology, 71(5), 575-580.

Lin, C. S. Y., Krishnan, A. V., Park, S. B., & Kiernan, M. C. (2011). Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Archives of neurology, 68(7), 862-869.

Lünemann, J.D., Nimmerjahn, F., Dalakas, M.C. (2015). Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nature Reviews Neurology, volume 11, 80-89.

Merkies, I. S. J., van Nes, S. I., Hanna, K., Hughes, R. A. C., & Deng, C. (2010). Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. Journal of Neurology, Neurosurgery & Psychiatry, 81(11), 1194-1199.

Nobile-Orazio, E., Cocito, D., Jann, S., Uncini, A., Beghi, E., Messina, P., ... & IMC Trial Group. (2012). Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. The Lancet Neurology,11(6), 493-502.

Patwa, H. S., Chaudhry, V., Katzberg, H., Rae-Grant, A. D., & So, Y. T. (2012). Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Querol, L., Rojas‐Garcia, R., Casasnovas, C., Sedano, M. J., Muñoz‐Blanco, J. L., Alberti, M. A., ... & Illa, I. (2013). Long‐term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study. Muscle & nerve, 48(6), 870-876.

Sorgun, M. H., Sener, H. O., Yucesan, C., & Yucemen, N. (2014). Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis.Neurological Sciences, 35(6), 891-896.

van der Pol, W. L., Cats, E. A., & van den Berg, L. H. (2010). Intravenous immunoglobulin treatment in multifocal motor neuropathy. Journal of clinical immunology, 30(1), 79-83.

van Schaik, I. N., Eftimov, F., van Doorn, P. A., Brusse, E., van den Berg, L. H., van der Pol, W. L., ... & Vermeulen, M. (2010). Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. The Lancet Neurology, 9(3), 245-253.

van Schaik, I. N., van den Berg, L. H., de Haan, R., & Vermeulen, M. (2005). Intravenous immunoglobulin for multifocal motor neuropathy. The Cochrane Library.

Vlam, L., Cats, E. A., Willemse, E., Franssen, H., Medic, J., Piepers, S., ... & van der Pol, W. L. (2013). Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. Journal of Neurology, Neurosurgery & Psychiatry, jnnp-2013.

Vlam, L., van der Pol, W. L., Cats, E. A., Straver, D. C., Piepers, S., Franssen, H., & van den Berg, L. H. (2012). Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nature Reviews Neurology, 8(1), 48-58.